5 results
To determine the safety and efficacy of Dimebon in patients with mild to moderate Huntington Disease
Primary Objective: The objective of this study is to asses whether or not the use of four implants in the augmented maxilla is as effective on the improvement of the patient*s oral functioning measured with the MFIQ as the use of six…
To determine the benefit of Dimebon as compared to placebo on the primary measure of cognition and memory, the Alzheimer*s Disease Assessment Scale * cognitive subscale (ADAS-cog); andTo determine the benefit of Dimebon as compared to placebo on the…
To evaluate the long-term safety and tolerability of Dimebon in AD patients who have successfully completed 26 weeks of blinded treatment in the CONNECTION Study (DIM14) (hereafter referred to as *CONNECTION*).
To test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD ascompared with placebo in patients with mild AD dementia.